Acute interstitial nephritis secondary to vedolizumab

Simpson, Nicholas; Seenan, John Paul; Patel, Rajan; Kipgen, David

doi:10.1136/bcr-2021-243568

Cited by 7 publications

(5 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Vedolizumab-induced AIN has been described in several case reports in the past few years 7–9. These are summarised in table 1.…”

Section: Discussionmentioning

confidence: 99%

“…The efficacy of vedolizumab has previously been demonstrated in the GEMINI trials for both induction and maintenance of remission in refractory UC 3. Vedolizumab-induced AIN has been demonstrated in prior case reports including where vedolizumab was successfully retrialled with high dose prednisone prophylaxis at the time of infusion 7–9. AIN associated with other integrin inhibitors has not been reported to date.…”

Section: Introductionmentioning

confidence: 88%

“…Given the temporal relationship to his dose of vedolizumab and his first AKI, and the fact that this drug has been associated with interstitial nephritis in the past,7–9 a vedolizumab-induced AIN was felt to be the most likely diagnosis.…”

Section: Differential Diagnosismentioning

confidence: 99%

See 2 more Smart Citations

Vedolizumab-induced acute interstitial nephritis with failure of steroid prophylaxis on vedolizumab rechallenge

O'Leary,

Wong,

Wilson

2023

BMJ Case Rep

View full text Add to dashboard Cite

Acute interstitial nephritis (AIN) is a common cause of acute kidney injury and renal failure. It is typically drug induced but can also be idiopathic or secondary to chronic infective or inflammatory conditions. Recent case reports suggest vedolizumab can be a causative agent for AIN. We report the case of a young man who presented with renal failure, fevers and constitutional symptoms. He had a complex history of refractory ulcerative colitis, prior colectomy and ileo-pouch-anal anastomosis with recurrent pouchitis. He had been receiving regular vedolizumab infusions for 6 months by the time of his presentation. A renal biopsy 4 months into his follow-up demonstrated AIN. Steroid prophylaxis with vedolizumab was trialled but ultimately failed, with worsening AIN and incomplete renal function recovery. To our knowledge, this is the first case of vedolizumab-induced AIN demonstrating a failure of steroid prophylaxis to prevent recurrence of AIN following vedolizumab rechallenge.

show abstract

“…Vedolizumab-induced AIN has been described in several case reports in the past few years 7–9. These are summarised in table 1.…”

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 88%

See 1 more Smart Citation

Vedolizumab-induced acute interstitial nephritis with failure of steroid prophylaxis on vedolizumab rechallenge

O'Leary,

Wong,

Wilson

2023

BMJ Case Rep

View full text Add to dashboard Cite

show abstract

“…We present the novel finding of a higher risk of developing AKI in patients with IBD. To our knowledge, existing evidence is confined to case reports (40–42). In absolute terms, 3.6% of the patients in our study suffered an AKI during the first decade after IBD diagnosis, a proportion larger than that of other well-documented extraintestinal manifestations such as, for instance, ankylosing spondylitis (present in 2.1% of IBD cases in our study).…”

Section: Discussionmentioning

confidence: 99%

Absolute and Relative Risks of Kidney and Urological Complications in Patients With Inflammatory Bowel Disease

Yang,

Ludvigsson,

Olén

et al. 2023

Am J Gastroenterol

View full text Add to dashboard Cite

Background: The burden of kidney and urological complications in patients with inflammatory bowel disease (IBD) remains poorly characterized. Methods: We analyzed association between developing IBD (as a time-varying exposure) and relative risks of receiving diagnoses of chronic kidney disease (CKD), acute kidney injury (AKI), or kidney stones, and experiencing a clinically-relevant decline in estimated glomerular filtration rate (eGFR) (CKD progression; composite of kidney failure or an eGFR decline ≥30%) in 1,682,795 individuals seeking healthcare in Stockholm, Sweden, during 2006-2018. We quantified 5- and 10-year absolute risks of these complications in a parallel matched cohort of IBD cases and random controls matched (1:5) on sex, age, and eGFR. Results: During median 9-years, 10,117 participants developed IBD. Incident IBD was associated with higher risks of kidney-related complications compared with non-IBD periods: HR (95% CI) was 1.24 (1.10-1.40) for receiving a CKD diagnosis, 1.11 (1.00-1.24) for CKD progression. For absolute risks, 11.8% IBD cases had a CKD event within 10-year. Of these, 6.4% received a CKD diagnosis, and 7.9% reached CKD progression. The risks of AKI (HR 1.97 [1.70-2.29]; 10-y absolute risk 3.6%), kidney stones (HR 1.69 [1.48-1.93]; 10-y absolute risk 5.6%) were also elevated. Risks were similar in Crohn’s disease and ulcerative colitis. Conclusion: More than 10% of IBD patients developed CKD within 10-year from diagnosis, with many not being identified through diagnostic codes. This, together with their elevated AKI and kidney stone risks, highlights the need of established protocols for kidney function monitoring and referral to nephrological/urological care for IBD patients.

show abstract

“…(41,42) Podobně byl také vedolizumab, humanizovaná monoklonální protilátka, která se specificky váže na integrin α4β7, v několika kazuistických sděleních označen za příčinu léky indukované TIN u pacienta s IBD. (43)(44)(45)…”

Section: Léky Indukované Postižení Ledvin U Pacientů S Ibdunclassified

Renal involvement in pediatric inflammatory bowel disease

Švábová,

Bauer,

Gonsorčíková

et al. 2023

Ces-slov Pediat

View full text Add to dashboard Cite

Pediatrická klinika, 1. lékařská fakulta, Univerzita Karlova a Fakultní Thomayerova nemocnice souhrn Švábová e, bauer D, Gonsorčíková L, Zieg J. renální postižení u pediatrických pacientů se zánětlivým střevním onemocněním Incidence zánětlivých střevních onemocnění celosvětově stoupá, a to zejména v dětské populaci. Zánětlivá střevní onemocnění mohou být doprovázena extraintestinální manifestací. Nejčastěji jsou kromě střev postiženy klouby, kůže, žlučové cesty a oči. Dalším orgánem, který může být v rámci základního onemocnění zasažen, jsou ledviny. Nejobvyklejší renální projevy zánětlivých střevních onemocnění zahrnují nefrolitiázu a dále také onemocnění renálního parenchymu -tubulointersticiální nefritidu, glomerulonefritidu a amyloidózu. V našem přehledovém článku se zaměřujeme na spektrum renálních chorob asociovaných se zánětlivými střevními onemocněními.

show abstract

Acute interstitial nephritis secondary to vedolizumab

Cited by 7 publications

References 12 publications

Vedolizumab-induced acute interstitial nephritis with failure of steroid prophylaxis on vedolizumab rechallenge

Vedolizumab-induced acute interstitial nephritis with failure of steroid prophylaxis on vedolizumab rechallenge

Absolute and Relative Risks of Kidney and Urological Complications in Patients With Inflammatory Bowel Disease

Renal involvement in pediatric inflammatory bowel disease

Contact Info

Product

Resources

About